2016
DOI: 10.1111/ene.13222
|View full text |Cite
|
Sign up to set email alerts
|

People with epilepsy receive more statins than the general population but have no higher cardiovascular risk: results from a cross‐sectional study

Abstract: People with epilepsy had more dyslipidemia, related to EIAEDs, and lower cardiovascular risk but still took more statins than the general population. Physicians should use clinical judgement to decide on further treatment of CVRFs in PWE who are below the recommended risk threshold for treatment and should consider lipid abnormalities a potential side-effect of EIAEDs. Other therapy options may need to be evaluated before starting lipid-lowering treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
9
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 29 publications
0
9
0
Order By: Relevance
“…Based on previous research 41 , the three CVD major risk factors were defined as follows: diabetes as the use of hypoglycemic agents, a self-reported history of diabetes, or a FPG ≥ 7.0 mmol/L or more 37 ; hypertension as resting SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or the self-reported current treatment for hypertension with antihypertensive medication 42 ; dyslipidemia as using lipid-lowering drugs or having one or more of the following: TG ≥ 1.7 mmol/L, TC ≥ 5.18 mmol/L, HDL-C < 1.04 mmol/L, and LDL-C ≥ 3.37 mmol/L 43 .…”
Section: Methodsmentioning
confidence: 99%
“…Based on previous research 41 , the three CVD major risk factors were defined as follows: diabetes as the use of hypoglycemic agents, a self-reported history of diabetes, or a FPG ≥ 7.0 mmol/L or more 37 ; hypertension as resting SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or the self-reported current treatment for hypertension with antihypertensive medication 42 ; dyslipidemia as using lipid-lowering drugs or having one or more of the following: TG ≥ 1.7 mmol/L, TC ≥ 5.18 mmol/L, HDL-C < 1.04 mmol/L, and LDL-C ≥ 3.37 mmol/L 43 .…”
Section: Methodsmentioning
confidence: 99%
“…In contrast, a study by Vicanco-Hidalgo et al [33] concluded that, despite a higher percentage of dyslipidemia in epileptic patients, they do not have a greater cardiovascular risk. In the above study compared to healthy people, epileptic individuals had a lower rate of hypertension and diabetes [33], what indicates the need for a better assessment of epileptic patients prior to statin treatment. In our study, patients were treated with various antiepileptic drugs, both in mono-and polytherapy.…”
Section: Discussionmentioning
confidence: 85%
“…In some studies, the monotherapy with old-generation drugs, such as carbamazepine, valproic acid, and phenytoin, was associated with an increase in cardiovascular risk [32]. In contrast, a study by Vicanco-Hidalgo et al [33] concluded that, despite a higher percentage of dyslipidemia in epileptic patients, they do not have a greater cardiovascular risk. In the above study compared to healthy people, epileptic individuals had a lower rate of hypertension and diabetes [33], what indicates the need for a better assessment of epileptic patients prior to statin treatment.…”
Section: Discussionmentioning
confidence: 99%
“…We defined the same four signatures for cardiometabolic risk factors in 2008 and 2017 (also see online supplementary table 1): (1) Obesity: BMI≥28 kg/m 21–23. (2) Hypertension: blood pressure ≥140/90 mm Hg and/or self-reported history of hypertension 24. (3) Dyslipidaemia: LDL-C ≥4.14 mmol/L and/or self-reported dyslipidaemia 25.…”
Section: Methodsmentioning
confidence: 99%